亚洲理论在线观看,中文字幕一区日韩精品,色一乱一伦一图一区二区精品,亚洲日本一区二区三区在线

掃碼關注公眾號           掃碼咨詢技術支持           掃碼咨詢技術服務
  
客服熱線:400-901-9800  客服QQ:4009019800  技術答疑  技術支持  質量反饋  人才招聘  關于我們  聯系我們
美女无遮挡免费视频网站,中文字幕久精品免费视频,少妇人妻无码精品视频
首頁 > 產品中心 > 一抗 > 產品信息
Rabbit Anti-KCTD7  antibody (bs-11729R)  
~~~促銷代碼KT202411~~~
訂購熱線:400-901-9800
訂購郵箱:sales@www.chomd.com.cn
訂購QQ:  400-901-9800
技術支持:techsupport@www.chomd.com.cn
說明書: 50ul  100ul  200ul
50ul/1180.00元
100ul/1980.00元
200ul/2800.00元
大包裝/詢價

產品編號 bs-11729R
英文名稱 Rabbit Anti-KCTD7  antibody
中文名稱 鉀離子通道多聚體結構域蛋白7抗體
別    名 BTB/POZ domain containing protein KCTD7; EPM3; FLJ32069; Potassium channel tetramerisation domain containing 7; KCTD7_HUMAN.  
研究領域 細胞生物  神經生物學  通道蛋白  細胞膜受體  
抗體來源 Rabbit
克隆類型 Polyclonal
交叉反應 Human (predicted: Mouse,Rat,Rabbit,Pig,Sheep,Cow,Chicken,Dog,Horse)
產品應用 WB=1:500-2000,IHC-P=1:100-500,IHC-F=1:100-500,Flow-Cyt=1ug/test,ICC/IF=1:100-500,IF=1:100-500,ELISA=1:5000-10000
not yet tested in other applications.
optimal dilutions/concentrations should be determined by the end user.
理論分子量 33kDa
細胞定位 細胞漿 細胞膜 
性    狀 Liquid
濃    度 1mg/ml
免 疫 原 KLH conjugated synthetic peptide derived from human KCTD7: 112-180/289 
亞    型 IgG
純化方法 affinity purified by Protein A
緩 沖 液 0.01M TBS (pH7.4) with 1% BSA, 0.02% Proclin300 and 50% Glycerol.
保存條件 Shipped at 4℃. Store at -20℃ for one year. Avoid repeated freeze/thaw cycles.
注意事項 This product as supplied is intended for research use only, not for use in human, therapeutic or diagnostic applications.
PubMed PubMed
產品介紹 Epilepsy affects about 0.5% of the world’s population and has a large genetic component. Epilepsy results from an electrical hyperexcitability in the central nervous system. Potassium channels are important regulators of electrical signaling, determining the firing properties and responsiveness of a variety of neurons. Benign familial neonatal convulsions (BFNC), an autosomal dominant epilepsy of infancy, has been shown to be caused by mutations in the KCNQ2 or the KCNQ3 potassium channel genes. KCNQ2 and KCNQ3 are voltage-gated potassium channel proteins with six putative transmembrane domains. Both proteins display a broad distribution within the brain, with expression patterns that largely overlap.

Function:
The KCTD gene family, including KCTD7, encode predicted proteins that contain N terminal domain that is homologous to the T1 domain in voltage gated potassium channels. KCTD7 displays a primary sequence and hydropathy profile indicating intracytoplasmic localization. There are two named isoforms.

Subunit:
May be involved in the control of excitability of cortical neurons

Subcellular Location:
Cell membrane. Cytoplasm, cytosol.

DISEASE:
efects in KCTD7 are the cause of epilepsy, progressive myoclonic 3, with or without intracellular inclusions (EPM3) [MIM:611726]. EPM3 is an autosomal recessive, severe, progressive myoclonic epilepsy with early-onset. Multifocal myoclonic seizures begin between 16 and 24 months of age after normal initial development. Neurodegeneration and regression occur with seizure onset. Other features include mental retardation, dysarthria, truncal ataxia, and loss of fine finger movements. EEG shows slow dysrhythmia, multifocal and occasionally generalized epileptiform discharges. In some patients, ultrastructural findings on skin biopsies identify intracellular accumulation of autofluorescent lipopigment storage material, consistent with neuronal ceroid lipofuscinosis.
Note=Defects in KCTD7 are a cause of opsoclonus-myoclonus ataxia-like syndrome. Opsoclonus myoclonus ataxia syndrome (OMS) is a rare pervasive and frequently permanent disorder that usually develops in previously healthy children with normal premorbid psychomotor development and characterized by association of abnormal eye movements (opsoclonus), severe dyskinesia (myoclonus), cerebellar ataxia, functional regression, and behavioral problems. The syndrome is considered to be an immune-mediated disorder and may be tumor-associated or idiopathic. OMS is one of a few steroid responsive disorders of childhood. KCTD7 mutations have been found in a patient with an atypical clinical presentation characterized by non-epileptic myoclonus and ataxia commencing in early infancy, abnormal opsoclonus-like eye movements, improvement of clinical symptoms under steroid treatment, and subsequent development of generalized epilepsy (PubMed:22638565).

Similarity:
Contains 1 BTB (POZ) domain.

SWISS:
Q96MP8

Gene ID:
154881

Database links:

Entrez Gene: 417547 Chicken

Entrez Gene: 100124502 Cow

Entrez Gene: 154881 Human

Entrez Gene: 212919 Mouse

Entrez Gene: 688993 Rat

Omim: 611725 Human

SwissProt: Q5ZJP7 Chicken

SwissProt: A4IFB4 Cow

SwissProt: Q96MP8 Human

SwissProt: Q8BJK1 Mouse

SwissProt: B1WC97 Rat

Unigene: 546627 Human

Unigene: 55812 Mouse

Unigene: 103510 Rat



產品圖片
Blank control: Hela. Primary Antibody (green line): Rabbit Anti-KCTD7 antibody (bs-11729R) Dilution: 1μg /10^6 cells; Isotype Control Antibody (orange line): Rabbit IgG . Secondary Antibody : Goat anti-rabbit IgG-PE Dilution: 1μg /test. Protocol The cells were fixed with 4% PFA (10min at room temperature)and then permeabilized with 20% PBST for 20 min atroom temperature. The cells were then incubated in 5%BSA to block non-specific protein-protein interactions for 30 min at at room temperature .Cells stained with Primary Antibody for 30 min at room temperature. The secondary antibody used for 40 min at room temperature. Acquisition of 20,000 events was performed.
版權所有 2004-2026 www.www.chomd.com.cn 北京博奧森生物技術有限公司
通過國際質量管理體系ISO 9001:2015 GB/T 19001-2016    證書編號: 00124Q34771R2M/1100
通過國際醫療器械-質量管理體系ISO 13485:2016 GB/T 42061-2022    證書編號: CQC24QY10047R0M/1100
京ICP備05066980號-1         京公網安備110107000727號